Anti-AEBP-1 Rabbit Polyclonal Antibody

Rabbit Polyclonal
WB
Citation tracking pending
Rabbit polyclonal antibodies raised against human AEBP-1, validated for Western blot applications.
Host
Rabbit, Polyclonal
Reactivity
Validated- Human Potential-
UniProt
Q8IUX7
Size
100ug
Cat. #
RP3AEBP1

In stock

SKU
RP-AEBP1

Options

As low as: $130.00

Target Overview

Adipocyte enhancer-binding protein 1 (AEBP-1, UniProt Q8IUX7) is a 1,158-residue secreted protein that functions as a positive regulator of collagen fibrillogenesis. As an extracellular matrix organizer, AEBP-1 is involved in matrix remodeling processes across multiple tissue contexts. The protein is also known as aortic carboxypeptidase-like protein, though its carboxypeptidase activity and substrate specificity remain areas of active investigation. AEBP-1 is expressed in fibroblasts and adipocytes and is secreted into the extracellular space, where it interacts with collagen fibrils during matrix assembly. Researchers study AEBP-1 in the context of fibrotic disease, extracellular matrix remodeling, cardiovascular pathology, and connective tissue disorders. Recent work has implicated AEBP-1 in cardiac fibrosis, endometriosis-associated fibrogenesis, and Ehlers-Danlos syndrome. The four rabbit polyclonal antibodies in this series were raised against the aminoterminal region of full-length human AEBP-1 and are validated for detection in Western blot, immunohistochemistry, and immunofluorescence.

Background

AEBP-1 was originally identified as a transcriptional regulator but is now recognized primarily for its extracellular role in collagen fibrillogenesis and matrix organization. The protein is secreted by fibroblasts and other mesenchymal cells and localizes to the extracellular matrix, where it modulates collagen fibril assembly and cross-linking. This function places AEBP-1 at the center of tissue remodeling processes in development, wound healing, and pathological fibrosis. Dysregulated AEBP-1 expression has been observed in multiple fibrotic conditions, and recent single-cell profiling studies have identified AEBP-1-expressing fibroblast subpopulations as key drivers of fibrogenesis in endometriosis (Huang et al., 2026).

Genetic variants in AEBP1 are associated with Ehlers-Danlos syndrome classical-like type 2, a connective tissue disorder characterized by skin hyperextensibility, joint hypermobility, and gastrointestinal complications. Novel splice-site variants continue to be reported, expanding the clinical phenotype associated with AEBP1 dysfunction. In cardiovascular disease, AEBP-1 has emerged as a potential therapeutic target in heart failure, where its inhibition may reduce pathological fibrosis and improve cardiac remodeling. Experimental models suggest that AEBP-1 blockade can attenuate collagen deposition and preserve ventricular function, supporting its role as a pro-fibrotic mediator.

AEBP-1 expression is also under investigation in proliferative vitreoretinal diseases and other conditions involving aberrant extracellular matrix remodeling. The protein's dual identity as both a carboxypeptidase-like protein and a matrix organizer continues to drive mechanistic studies aimed at defining its enzymatic activity, substrate repertoire, and regulatory interactions within the matrix compartment.

References

  1. Huang E et al (2026) Single-cell profiling and machine learning identify cuproptosis-related fibroblast subpopulations and fibrogenesis modulator AEBP1 in endometriosis. Apoptosis. PubMed · DOI
  2. Drakos S et al (2026) Adipocyte Enhancer Binding Protein 1 (AEBP1) Inhibition as a Potential Anti-Fibrotic Therapy in Heart Failure. Res Sq. PubMed · DOI
  3. Nakahara H et al (2026) Gastrointestinal involvement in Ehlers-Danlos syndrome classical-like type 2 associated with a novel AEBP1 splice-site variant. J Hum Genet. PubMed · DOI
  4. Duveau C et al (2026) Key role of transcription factors network in proliferative vitreoretinal diseases development. Cell Biosci. PubMed · DOI
  5. Xu JY (2026) Bioinformatics analysis implicates ferroptosis and key hub genes in the pathogenesis of endometriosis. J Obstet Gynaecol. PubMed · DOI

Additional Specifications

Size 100 µg
Gene Symbol AEBP1
UniProt ID Q8IUX7
Host Species Rabbit
Species Reactivity Validated- Human
Potential-
Pack Size 100ug
Immunogen (Aminoterminal end full length AEBP1)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 26-76.
Immunogen (Aminoterminal end 845 AA AEBP1)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 26-76.
Immunogen (Catalytic domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 563-904.
Immunogen (DNA-binding domain)Immunogen is proprietary and confidential. Immunogen generated in amino acid region 390-555.
Alternate Names AEBP1, Adipocyte enhancer-binding protein 1, AE-binding protein 1, Aortic carboxypeptidase-like protein

Frequently Asked Questions

What molecular weight band should I expect for AEBP-1 on Western blot?

AEBP-1 runs at approximately 130 kDa on reducing SDS-PAGE, though the calculated molecular weight from the 1,158-residue sequence is closer to 127 kDa. Post-translational modifications including glycosylation may contribute to the observed migration. Because AEBP-1 is a secreted extracellular matrix protein, you may also detect lower molecular weight bands corresponding to proteolytic fragments or splice variants in some tissue lysates. Conditioned media from fibroblasts or adipocytes typically yields cleaner results than whole-cell lysates for detecting the full-length secreted form.

What starting dilution should I use for AEBP-1 Western blot?

Start at 1:1000 dilution in blocking buffer for overnight incubation at 4°C. This rabbit polyclonal has been validated at this dilution for human samples. If signal is weak, you can increase antibody concentration to 1:500, but test specificity with a blocking peptide or AEBP-1 knockdown control. For conditioned media samples where AEBP-1 is enriched, 1:2000 may be sufficient. Always include a positive control such as lysate from cultured human fibroblasts or tissue known to express AEBP-1, such as aorta or adipose.

Is this AEBP-1 antibody cross-reactive with mouse or rat samples?

This antibody has been validated for human AEBP-1 detection. Cross-reactivity with mouse or rat has not been experimentally validated by Triple Point Biologics. Human and mouse AEBP-1 share approximately 75% sequence identity, so cross-reactivity is possible but not guaranteed. If you are working with rodent samples, we recommend running a preliminary Western blot with appropriate positive controls and verifying band specificity through siRNA knockdown or comparison with published literature reporting AEBP-1 expression patterns in your tissue of interest.

What sample preparation works best for detecting secreted AEBP-1?

Since AEBP-1 is secreted into the extracellular space, conditioned media from cultured cells often provides the best signal with minimal background. Collect serum-free media after 24-48 hours of conditioning, then concentrate 10-20-fold using centrifugal filters (10 kDa cutoff). For tissue lysates, include extracellular matrix extraction steps or use RIPA buffer with protease inhibitors. Standard whole-cell lysis may under-represent AEBP-1 compared to methods that capture secreted and matrix-associated proteins. Avoid repeated freeze-thaw cycles, as AEBP-1 stability in solution has not been systematically characterized.

Does AEBP-1 have splice isoforms I need to account for?

The UniProt entry Q8IUX7 lists the canonical 1,158-residue isoform as the predominant form. While alternative splice variants have been reported in transcriptomic databases, their protein-level expression and functional significance remain unclear. Most published work focuses on the full-length secreted protein. If you observe multiple bands on Western blot beyond the expected 130 kDa species, consider proteolytic processing rather than splicing. AEBP-1 contains a carboxypeptidase-like domain, and cleavage products may appear in certain tissue contexts or disease states where matrix remodeling is active.

Can I use this antibody for immunohistochemistry on human tissue?

Triple Point Biologics antibodies are validated for Western blot; IHC application data is in progress, and this rabbit polyclonal format is compatible with standard IHC protocols. For AEBP-1 detection in formalin-fixed paraffin-embedded human tissue, antigen retrieval is typically required—citrate buffer (pH 6.0) heat-induced retrieval is a reasonable starting point. AEBP-1 localizes to the extracellular matrix in fibroblast-rich regions, so expect stromal staining rather than uniform cellular labeling. Optimal antibody dilution for IHC generally ranges from 1:100 to 1:400; empirical titration against your specific tissue type is recommended.

How should I store the AEBP-1 antibody and how long is it stable?

Store the antibody at -20°C in single-use aliquots to avoid repeated freeze-thaw cycles, which can compromise titer and increase aggregation. Polyclonal antibodies in glycerol-containing storage buffer are generally stable for at least one year under these conditions. For short-term use (up to one month), diluted working stocks can be kept at 4°C with 0.02% sodium azide as preservative, though we recommend preparing fresh dilutions for each experiment when possible. Do not store diluted antibody in Tris buffers above pH 8.5 or in the presence of primary amines that may interfere with subsequent conjugation if needed.

What controls should I include when detecting AEBP-1 in fibrosis models?

Include lysates or conditioned media from cultured human fibroblasts as a positive control, since AEBP-1 is robustly expressed in these cells. For specificity, run a parallel blot with antibody pre-incubated with blocking peptide if available, or compare wildtype versus AEBP-1 siRNA-treated samples. In fibrosis models, AEBP-1 expression is upregulated during active collagen deposition, so compare fibrotic versus non-fibrotic tissue from the same organ. Because AEBP-1 is secreted, measuring both tissue lysate and interstitial fluid or serum can provide complementary information about local versus systemic protein levels.

Validation imagery coming soon

Western blot validation figures for RP-AEBP1 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

Also known as:

  • AEBP1
  • Adipocyte enhancer-binding protein 1
  • AE-binding protein 1
  • Aortic carboxypeptidase-like protein
  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →